In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP) that has been shown to be highly effective at reducing...
Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to severe illness, morbidity, and mortality, particularly in sub-Saharan Africa.
These guidelines update the recommendations that were first released in 2018 ...
The primary audience for this guideline is national HIV programme managers, people living
with HIV, health-care providers and policy-makers in low- and middle-income countries. This
guideline update will be a useful resource for clinicians and should help to shape the priorities
of policy-makers in devel...
WHO promotes a public health approach to programming and delivering antiretroviral therapy (ART), which has enabled access to treatment and care for people living with HIV to be scaled up in resource-limited settings.
The 2016 WHO consolidated guidelines on the use of antiretroviral drugs for treating an...
These consolidated guidelines on HIV testing services (HTS) bring together existing and
new guidance on HTS across different settings and populations.
The World Health Organization (WHO) first released consolidated guidelines on HTS in
2015, in response to requests from Member States, national programme ...
Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection...
Background
The programmatic management of latent tuberculosis infection (LTBI) in populations most at risk of developing TB remains a critical activity to disrupt Mycobacterium tuberculosis transmission, as identified in the End TB Strategy. LTBI is defined as a state of persistent immune response to sti...
Since the release of the consolidated guidelines in 2015, new evidence has emerged. Consequently, in an effort to further support countries, programme managers, health workers and other stakeholders seeking to achieve national and international HIV goals, this 2016 update issues new recommendations and a...
Tests based on the detection of mycobacterial lipoarabinomannan (LAM) antigen in urine have
emerged as potential point-of-care tests for tuberculosis (TB). LAM antigen is a lipopolysaccharide
present in mycobacterial cell walls, which is released from metabolically active or degenerating
bacterial cells ...
The Consolidated guidelines on HIV testing services bring together existing guidance relevant to the provision of HIV testing services (HTS) and addresses issues and elements for effective delivery of HTS that are common in a variety of settings, contexts and diverse populations. In addition, this docume...
